The effect of pranlukast on alveolar exhaled nitric oxide in patients with asthma under inhaled corticosteroid therapy; Open-labeled, cross-over trial.

The effect of pranlukast on alveolar exhaled nitric oxide in patients with asthma under inhaled corticosteroid therapy; Open-labeled, cross-over trial. - Pranlukast and eNO in asthma under ICS therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003781

Enrollment

Registered

2010-06-18

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Asthma

Interventions

administration of oral pranlukast for 8 weeks continuation of present therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All participants of this study must meet the following requirements 1. Patients on asthma treated with inhaled corticosteroid therapy over 2 months. 2. Patients with no administration of pranlukast or other leukotriene receptor antagonist over recent 4 weeks.

Exclusion criteria

Exclusion criteria: Exclusion criterias are as follows. 1. Patients during asthmatic attack,or infectious disease to treat with priority. 2. Patients with history of hypersensitivity to pranlukast. 3. Patients with complications as pneumothorax or severe heart failure. 4. Judgement of attending physician.

Design outcomes

Primary

Measure	Time frame
Exhaled nitric oxide (bronchial NO flux and alveolar NO concentration) Plumonary function test (FEV1.0, V50, V25)	—

Secondary

Measure	Time frame
Peak Expiratory Flow Ratio Asthma Control Test (ACT)	—

Countries

Japan

Contacts

Public ContactTomoyuki Fujisawa

Hamamatsu University School of Medicine, University Hospital Department of Clinical Laboratory

fujisawa@hama-med.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026